Dr Christopher Burns is an accomplished and highly regarded medicinal chemist and drug discoverer. He was the lead inventor of the drugs momelotinib (recently approved by the US FDA) and lexibulin (underwent Phase 2 trials). He is an inventor on 29 patents and co-author of 68 scientific publications. Currently CEO and MD of ASX-listed Amplia Therapeutics, a company he co-founded, he has worked in both industry (Pfizer, Cytopia, Gilead) and academia (The University of Sydney, WEHI). He is a consultant to selected biotech companies, VCs and academic groups, and contributes to various academic committees.